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Sir, Spectral domain optical coherence tomography features in niacin maculopathy
We report the spectral domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) findings in a case of niacin maculopathy. To the best of our knowledge, only time domain OCT has been reported; SD-OCT yields better resolution of the affected retinal layers in this unusual disorder.
Case Report
A 57-year-old male presented with blurred vision in the right eye over the past 2 weeks. He reported taking 2000 mg of niacin daily for 5 months after suffering from myalgia related to statin therapy for hyperlipidemia. Visual acuity was 20/40 in the right eye and 20/20 in the left eye. Intraocular pressure was normal and slit lamp Eye Comment Reversible, angiographically silent, cystoid maculopathy due to high-dose niacin was first described by Gass in 1973. 1 Decades later, Spirn et al 2 and then Dajani and Lauer 3 demonstrated the time domain OCT findings that appeared to localize the cystoid spaces to the outer plexiform and inner nuclear layers. In contrast, SD-OCT demonstrates the spaces in the outer nuclear layer, the inner nuclear layer, and possibly the ganglion cell layer. There are two existing theories regarding the pathogenesis: Muller cell toxicity and engorgement, 4 and selective vascular permeability not allowing the passage of fluorescein. 3 Nicotinamide adenine dinucleotide, a metabolite of niacin, is highly active in chromatin function suggesting that derangement of nuclear metabolism might explain the appearance of cystoid spaces in the nuclear layers of the retina.
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The authors declare no conflict of interest. We congratulate Drs Verity and Rose on their excellent update and review of the management of acute thyroid eye disease. 1 They state that use of Botulinum toxin (BoNTA) for eyelid retraction in this disease state is inadvisable. Certainly, through a transcutaneous approach we agree that the correct placement of BoNTA without affecting the superior rectus or orbicularis oculi is variable in both its efficacy and effectiveness. 2 However in our experience, we find transconjunctival administration to be a much safer and predictable approach.
Injection of BoNTA through a transconjunctival approach is ideally suited for patients with active thyroid orbitopathy and moderate or severe eyelid retraction. It can be used as an adjunct to other supportive therapies. 3 Rather than using the standard 2.5 units of BoNTA that would achieve complete ptosis in patients without thyroid orbitopathy, we have found 5 units in 0.1 ml to be safe and effective in patients with thyroid eyelid retraction. This very rarely gives rise to severe or prolonged ptosis, and we have not encountered BoNTA-induced hypotropia or superior rectus underaction; a finding consistent with studies that have utilised even larger subconjunctival doses. 4, 5 Topical local anaesthetic is instilled and the upper eyelid is everted. A minimum dose of 2.5 units and maximum of 7.5 units (usual dose 5 units for scleral show 1-2 mm) BoNTA (Botox diluted 5 units/0.1 ml, Allergan Limited, UK) is administered via a single injection into the subconjunctival space at the superior margin of the central tarsal plate. Within 48 h, eyelid retraction and lagophthalmos improves and a better aesthetic appearance is achieved, particularly during active disease when patients may be unsuitable for surgical lowering.
